Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.65 |
| ▸ | CCR9 | P51686 | 2/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211807 | 0.85 | CCR2 (0.71) | CCR2CCR9NTRK1ABCB11CNR1 | |
| SCHEMBL6432426 | 0.85 | CCR2 (0.78) | CCR2CCR9NTRK1CNR1KDM4E | |
| SCHEMBL3202116 | 0.83 | CCR2 (0.54) | CCR2CCR9NTRK1ABCB11CNR1 | |
| SCHEMBL3212389 | 0.83 | CCR2 (0.61) | CCR2CCR9NTRK1ABCB11CNR1 | |
| SCHEMBL2005378 | 0.82 | CCR2 (0.73) | CCR2ABCB11 | |
| SCHEMBL4537700 | 0.82 | CCR2 (0.76) | CCR2ABCB11 | |
| SCHEMBL7423846 | 0.81 | CCR2 (0.74) | CCR2CCR9ABCB11 | |
| SCHEMBL3207445 | 0.80 | CCR2 (0.58) | CCR2CCR9NTRK1ABCB11CNR1 | |
| SCHEMBL3190280 | 0.80 | CCR2 (0.71) | CCR2CCR9NTRK1CNR1 | |
| SCHEMBL13422702 | 0.79 | CNR1 (0.80) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671080-B2 | 1-benzylindole-2-carboxamide derivatives | N.V. ORGANON (NL) | 2010-03-02 | — | — | US | disclosed |
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | N.V. ORGANON (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1940788-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. Organon (NL) | 2008-07-09 | — | — | EP | disclosed |
| WO-2006100208-A9 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | ORGANON NV (NL) | 2007-11-22 | — | — | WO | disclosed |
| WO-2006100208-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | CNR2, CNR1, HTR2C | CCR2 830/4885CCR9 3642/4885NTRK1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.